Followers | 813 |
Posts | 71327 |
Boards Moderated | 2 |
Alias Born | 01/30/2003 |
Wednesday, November 11, 2015 8:31:11 AM
MEI Pharma: ASH Abstract Data Supports Advancement Of Pracinostat In MDS And AML
Nov. 11, 2015 7:54 AM ET | About: MEI Pharma, Inc. (MEIP)
Disclosure: I am/we are long MEIP. (More...)
Summary
Hazard ratios strongly favor Pracinostat compared to placebo in MDS trial for survival, progression free survival and event free survival in patients tolerating combo.
Abstract reveals goal of 12 month median overall survival already achieved in elderly AML trial.
Management communicated that as of today the median overall survival is still not reached in AML trial, adding at least another 3 months to abstract data.
Sitting at ~$60M market cap, near cash on hand, I expect shares to run-up in anticipation of ASH and much higher following results and analyst feedback.
I wrote an article last week detailing why investors should buy MEI Pharma (NASDAQ:MEIP) before the American Society of Hematology (NYSE:ASH) meeting on Decemeber 7th where updated data will be presented for their lead drug Pracinostat in Acute Myeloid Leukemia and Myelodysplastic Syndrome. The two abstracts for the presentation were released last Thursday and the data is more impressive than I anticipated for both MDS and AML. Investors sold on the news, likely taking profits from the ~30% run-up the last two weeks. I've been getting a lot of emails regarding my take on the abstracts so I thought it would be easier to release a brief summary explaining the updated data which clearly illustrates that the target overall survival metric needed to move Pracinostat into Phase 3 for elderly AML has already been achieved and why the MDS indication could be back on the table. I reiterate my position and look for a nice run-up leading into ASH.
SA Link.
http://seekingalpha.com/article/3675316-mei-pharma-ash-abstract-data-supports-advancement-of-pracinostat-in-mds-and-aml
Recent MEIP News
- MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344 • Business Wire • 04/11/2024 12:02:00 PM
- MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients • Business Wire • 04/11/2024 12:00:00 PM
- MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum • Business Wire • 04/10/2024 12:00:00 PM
- MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia • Business Wire • 03/26/2024 12:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/29/2024 05:15:45 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/21/2024 09:00:17 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/20/2024 10:33:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 10:05:14 PM
- MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights • Business Wire • 02/13/2024 10:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2024 09:00:08 PM
- MEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024 • Business Wire • 01/16/2024 10:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2023 10:00:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/22/2023 09:00:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/21/2023 02:26:37 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/21/2023 02:25:28 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/18/2023 09:00:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 09:00:09 PM
- MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023 • Business Wire • 12/11/2023 05:00:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 11/15/2023 01:59:13 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:06:11 PM
- MEI Pharma Reports First Quarter Fiscal Year 2024 Results and Operational Highlights • Business Wire • 11/09/2023 09:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:00:26 PM
FEATURED Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM
Avant Technologies to Implement AI-Empowered, Zero Trust Architecture in Its Data Centers • AVAI • Apr 29, 2024 8:00 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM